Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Sell
13
SINT Quote, Financials, Valuation and Earnings
Last price:
$2.77
Seasonality move
:
-19.22%
Day range:
$2.71 - $2.83
52-week range:
$1.71 - $8.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.66x
P/B ratio:
1.14x
Volume:
44.9K
Avg. volume:
165.1K
1-year change:
-48.42%
Market cap:
$6.9M
Revenue:
$1.2M
EPS (TTM):
-$13.12
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SINT
SINTX Technologies
|
$400K | -$0.79 | 5.82% | -78.12% | $28.00 |
|
IVF
INVO Fertility
|
$1.7M | -- | -8.8% | -- | -- |
|
NMTC
NeuroOne Medical Technologies
|
$1.8M | -- | 120.4% | -57.14% | $1.45 |
|
NTRB
Nutriband
|
$665K | -$0.17 | 59.2% | -13.33% | $15.00 |
|
NVNO
enVVeno Medical
|
-- | -$0.28 | -- | -9.68% | $12.50 |
|
XAIR
Beyond Air
|
$1.7M | -- | 155.97% | -- | $2.25 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SINT
SINTX Technologies
|
$2.77 | $28.00 | $6.9M | -- | $0.00 | 0% | 2.66x |
|
IVF
INVO Fertility
|
$0.82 | -- | $1.8M | -- | $0.00 | 0% | 0.08x |
|
NMTC
NeuroOne Medical Technologies
|
$0.72 | $1.45 | $36M | -- | $0.00 | 0% | 3.74x |
|
NTRB
Nutriband
|
$8.12 | $15.00 | $90.4M | -- | $0.00 | 0% | 37.58x |
|
NVNO
enVVeno Medical
|
$4.27 | $12.50 | $74.9M | -- | $0.00 | 0% | 416.56x |
|
XAIR
Beyond Air
|
$3.24 | $2.25 | $15M | -- | $0.00 | 0% | 2.96x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SINT
SINTX Technologies
|
2.11% | 1.788 | 1.98% | 2.98x |
|
IVF
INVO Fertility
|
65.97% | 1.151 | 20.29% | 0.05x |
|
NMTC
NeuroOne Medical Technologies
|
-- | 0.459 | -- | 0.93x |
|
NTRB
Nutriband
|
3.43% | 1.334 | 0.24% | 3.31x |
|
NVNO
enVVeno Medical
|
-- | 1.389 | -- | -- |
|
XAIR
Beyond Air
|
41.93% | 0.040 | 42.16% | 1.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SINT
SINTX Technologies
|
$45K | -$2.4M | -177.02% | -180.99% | -783.16% | -$1.4M |
|
IVF
INVO Fertility
|
$592.3K | -$2.5M | -313.33% | -714.24% | -1044.01% | -$3.6M |
|
NMTC
NeuroOne Medical Technologies
|
$771.1K | -$2.7M | -281.01% | -281.01% | -163.76% | -$59.3K |
|
NTRB
Nutriband
|
$252K | -$1.4M | -100.04% | -102.63% | -207.21% | -$1.3M |
|
NVNO
enVVeno Medical
|
-- | -$5M | -- | -- | -- | -$4M |
|
XAIR
Beyond Air
|
-$32K | -$7.2M | -146.65% | -218.07% | -649.57% | -$8.5M |
SINTX Technologies vs. Competitors
-
Which has Higher Returns SINT or IVF?
INVO Fertility has a net margin of -787.63% compared to SINTX Technologies's net margin of -1063.02%. SINTX Technologies's return on equity of -180.99% beat INVO Fertility's return on equity of -714.24%.
Company Gross Margin Earnings Per Share Invested Capital SINTSINTX Technologies15.46% -$1.29 $6.2M IVFINVO Fertility36.18% -$12.53 $9.8M -
What do Analysts Say About SINT or IVF?
SINTX Technologies has a consensus price target of $28.00, signalling upside risk potential of 910.83%. On the other hand INVO Fertility has an analysts' consensus of -- which suggests that it could grow by 631.8%. Given that SINTX Technologies has higher upside potential than INVO Fertility, analysts believe SINTX Technologies is more attractive than INVO Fertility.
Company Buy Ratings Hold Ratings Sell Ratings SINTSINTX Technologies1 0 0 IVFINVO Fertility0 0 0 -
Is SINT or IVF More Risky?
SINTX Technologies has a beta of 0.713, which suggesting that the stock is 28.749% less volatile than S&P 500. In comparison INVO Fertility has a beta of 2.045, suggesting its more volatile than the S&P 500 by 104.471%.
-
Which is a Better Dividend Stock SINT or IVF?
SINTX Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. INVO Fertility offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SINTX Technologies pays -- of its earnings as a dividend. INVO Fertility pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SINT or IVF?
SINTX Technologies quarterly revenues are $291K, which are smaller than INVO Fertility quarterly revenues of $1.6M. SINTX Technologies's net income of -$2.3M is higher than INVO Fertility's net income of -$17.4M. Notably, SINTX Technologies's price-to-earnings ratio is -- while INVO Fertility's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SINTX Technologies is 2.66x versus 0.08x for INVO Fertility. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SINTSINTX Technologies2.66x -- $291K -$2.3M IVFINVO Fertility0.08x -- $1.6M -$17.4M
-
Which has Higher Returns SINT or NMTC?
NeuroOne Medical Technologies has a net margin of -787.63% compared to SINTX Technologies's net margin of -163.76%. SINTX Technologies's return on equity of -180.99% beat NeuroOne Medical Technologies's return on equity of -281.01%.
Company Gross Margin Earnings Per Share Invested Capital SINTSINTX Technologies15.46% -$1.29 $6.2M NMTCNeuroOne Medical Technologies55.61% -$0.07 $1.1M -
What do Analysts Say About SINT or NMTC?
SINTX Technologies has a consensus price target of $28.00, signalling upside risk potential of 910.83%. On the other hand NeuroOne Medical Technologies has an analysts' consensus of $1.45 which suggests that it could grow by 100.42%. Given that SINTX Technologies has higher upside potential than NeuroOne Medical Technologies, analysts believe SINTX Technologies is more attractive than NeuroOne Medical Technologies.
Company Buy Ratings Hold Ratings Sell Ratings SINTSINTX Technologies1 0 0 NMTCNeuroOne Medical Technologies1 0 0 -
Is SINT or NMTC More Risky?
SINTX Technologies has a beta of 0.713, which suggesting that the stock is 28.749% less volatile than S&P 500. In comparison NeuroOne Medical Technologies has a beta of 0.749, suggesting its less volatile than the S&P 500 by 25.052%.
-
Which is a Better Dividend Stock SINT or NMTC?
SINTX Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroOne Medical Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SINTX Technologies pays -- of its earnings as a dividend. NeuroOne Medical Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SINT or NMTC?
SINTX Technologies quarterly revenues are $291K, which are smaller than NeuroOne Medical Technologies quarterly revenues of $1.4M. SINTX Technologies's net income of -$2.3M is lower than NeuroOne Medical Technologies's net income of -$2.3M. Notably, SINTX Technologies's price-to-earnings ratio is -- while NeuroOne Medical Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SINTX Technologies is 2.66x versus 3.74x for NeuroOne Medical Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SINTSINTX Technologies2.66x -- $291K -$2.3M NMTCNeuroOne Medical Technologies3.74x -- $1.4M -$2.3M
-
Which has Higher Returns SINT or NTRB?
Nutriband has a net margin of -787.63% compared to SINTX Technologies's net margin of -208.09%. SINTX Technologies's return on equity of -180.99% beat Nutriband's return on equity of -102.63%.
Company Gross Margin Earnings Per Share Invested Capital SINTSINTX Technologies15.46% -$1.29 $6.2M NTRBNutriband37.75% -$0.12 $5.3M -
What do Analysts Say About SINT or NTRB?
SINTX Technologies has a consensus price target of $28.00, signalling upside risk potential of 910.83%. On the other hand Nutriband has an analysts' consensus of $15.00 which suggests that it could grow by 84.73%. Given that SINTX Technologies has higher upside potential than Nutriband, analysts believe SINTX Technologies is more attractive than Nutriband.
Company Buy Ratings Hold Ratings Sell Ratings SINTSINTX Technologies1 0 0 NTRBNutriband1 0 0 -
Is SINT or NTRB More Risky?
SINTX Technologies has a beta of 0.713, which suggesting that the stock is 28.749% less volatile than S&P 500. In comparison Nutriband has a beta of 1.226, suggesting its more volatile than the S&P 500 by 22.565%.
-
Which is a Better Dividend Stock SINT or NTRB?
SINTX Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SINTX Technologies pays -- of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SINT or NTRB?
SINTX Technologies quarterly revenues are $291K, which are smaller than Nutriband quarterly revenues of $667.4K. SINTX Technologies's net income of -$2.3M is lower than Nutriband's net income of -$1.4M. Notably, SINTX Technologies's price-to-earnings ratio is -- while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SINTX Technologies is 2.66x versus 37.58x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SINTSINTX Technologies2.66x -- $291K -$2.3M NTRBNutriband37.58x -- $667.4K -$1.4M
-
Which has Higher Returns SINT or NVNO?
enVVeno Medical has a net margin of -787.63% compared to SINTX Technologies's net margin of --. SINTX Technologies's return on equity of -180.99% beat enVVeno Medical's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SINTSINTX Technologies15.46% -$1.29 $6.2M NVNOenVVeno Medical-- -$0.22 -- -
What do Analysts Say About SINT or NVNO?
SINTX Technologies has a consensus price target of $28.00, signalling upside risk potential of 910.83%. On the other hand enVVeno Medical has an analysts' consensus of $12.50 which suggests that it could grow by 192.74%. Given that SINTX Technologies has higher upside potential than enVVeno Medical, analysts believe SINTX Technologies is more attractive than enVVeno Medical.
Company Buy Ratings Hold Ratings Sell Ratings SINTSINTX Technologies1 0 0 NVNOenVVeno Medical1 0 0 -
Is SINT or NVNO More Risky?
SINTX Technologies has a beta of 0.713, which suggesting that the stock is 28.749% less volatile than S&P 500. In comparison enVVeno Medical has a beta of 0.932, suggesting its less volatile than the S&P 500 by 6.781%.
-
Which is a Better Dividend Stock SINT or NVNO?
SINTX Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. enVVeno Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SINTX Technologies pays -- of its earnings as a dividend. enVVeno Medical pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SINT or NVNO?
SINTX Technologies quarterly revenues are $291K, which are larger than enVVeno Medical quarterly revenues of --. SINTX Technologies's net income of -$2.3M is higher than enVVeno Medical's net income of -$4.5M. Notably, SINTX Technologies's price-to-earnings ratio is -- while enVVeno Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SINTX Technologies is 2.66x versus 416.56x for enVVeno Medical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SINTSINTX Technologies2.66x -- $291K -$2.3M NVNOenVVeno Medical416.56x -- -- -$4.5M
-
Which has Higher Returns SINT or XAIR?
Beyond Air has a net margin of -787.63% compared to SINTX Technologies's net margin of -697.4%. SINTX Technologies's return on equity of -180.99% beat Beyond Air's return on equity of -218.07%.
Company Gross Margin Earnings Per Share Invested Capital SINTSINTX Technologies15.46% -$1.29 $6.2M XAIRBeyond Air-2.78% -$0.09 $24.1M -
What do Analysts Say About SINT or XAIR?
SINTX Technologies has a consensus price target of $28.00, signalling upside risk potential of 910.83%. On the other hand Beyond Air has an analysts' consensus of $2.25 which suggests that it could grow by 1288.89%. Given that Beyond Air has higher upside potential than SINTX Technologies, analysts believe Beyond Air is more attractive than SINTX Technologies.
Company Buy Ratings Hold Ratings Sell Ratings SINTSINTX Technologies1 0 0 XAIRBeyond Air2 1 0 -
Is SINT or XAIR More Risky?
SINTX Technologies has a beta of 0.713, which suggesting that the stock is 28.749% less volatile than S&P 500. In comparison Beyond Air has a beta of 0.221, suggesting its less volatile than the S&P 500 by 77.879%.
-
Which is a Better Dividend Stock SINT or XAIR?
SINTX Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Beyond Air offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SINTX Technologies pays -- of its earnings as a dividend. Beyond Air pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SINT or XAIR?
SINTX Technologies quarterly revenues are $291K, which are smaller than Beyond Air quarterly revenues of $1.2M. SINTX Technologies's net income of -$2.3M is higher than Beyond Air's net income of -$8M. Notably, SINTX Technologies's price-to-earnings ratio is -- while Beyond Air's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SINTX Technologies is 2.66x versus 2.96x for Beyond Air. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SINTSINTX Technologies2.66x -- $291K -$2.3M XAIRBeyond Air2.96x -- $1.2M -$8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
How High Can SharkNinja Stock Go?
If you know popular consumer appliance brands Shark and Ninja,…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 12.76% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.4% over the past day.
Sell
42
VLCN alert for Jul 17
Volcon [VLCN] is up 195.74% over the past day.
